Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Radionuclide therapy for painful bone metastases - An Italian multicentre observational study
Autore:
Piffanelli, A; Dafermou, A; Giganti, M; Colamussi, P; Pizzocaro, C; Bestagno, M;
Indirizzi:
Univ Ferrara, Nucl Med Serv, I-44100 Ferrara, Italy Univ Ferrara FerraraItaly I-44100 Nucl Med Serv, I-44100 Ferrara, Italy Spedali Civili, I-25125 Brescia, Italy Spedali Civili Brescia Italy I-25125 dali Civili, I-25125 Brescia, Italy
Titolo Testata:
QUARTERLY JOURNAL OF NUCLEAR MEDICINE
fascicolo: 1, volume: 45, anno: 2001,
pagine: 100 - 107
SICI:
1125-0135(200103)45:1<100:RTFPBM>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONTROLLED TRIALS; PROSTATE-CANCER; SR-89 CHLORIDE; PALLIATION; EFFICACY;
Keywords:
prostate neoplasms; bone neoplasms secondary; strontium radioisotopes; palliative care, methods; radioisotopes; bone neoplasms, radiotherapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Piffanelli, A Univ Ferrara, Nucl Med Serv, Corso Giovecca 203, I-44100 Ferrara, Italy Univ Ferrara Corso Giovecca 203 Ferrara Italy I-44100 Italy
Citazione:
A. Piffanelli et al., "Radionuclide therapy for painful bone metastases - An Italian multicentre observational study", Q J NUCL M, 45(1), 2001, pp. 100-107

Abstract

Background. It has been affirmed that observational studies give analogousresults to randomised controlled ones. Methods. A multicentre observational trial was conducted between 1996-1998in order to evaluate the efficacy of palliative radionuclide therapy for bone metastases in a large number of patients. An evaluation was made on 510patients with prostate cancer and painful bone metastases, treated with a single iv. dose of Sr-89-chloride (527 treatments) or Re-186-HEDP (83 treatments), in 29 Italian Nuclear Medicine Departments. Eighty-one patients received up to five injections, totalling 100 retreatments. Patients were followed up for a period of 3 months-2 years. Results were expressed at four levels of response: excellent, good, mild, and nil. Results. Responses were excellent in 26.4%, good in 33.3%, mild in 21.3% and nil in 19% of all treatments, while good and excellent responses were obtained in 48% of retreatments. No statistically significant correlations mere found between response and age of patients, skeletal extension of tumour, pretherapeutic PSA levels, evidence of non-bony metastases, previous chemotherapy and/or external-beam radiotherapy; osteolytic lesions responded worse than osteoblastic or mixed ones. Hematological toxicity (mild to moderate), mainly affecting platelets, was observed in 25.5% of all treatments and in 38.9% of retreatments. No clear differences were found between the tworadiopharmaceuticals employed. Conclusions. Bearing in mind that observational studies can provide just as accurate results as randomised controlled trials, this study confirms themain findings of various Limited monocentre trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 22:56:24